The 3D Tissue Reforming Technology Platform is an innovative technology for producing organoid tissue modules.
By leveraging stem cell self-organization capabilities and the principles of human embryology, this platform enables the development of high-quality organoid-based regenerative therapeutics, designated as a national high-tech strategic technology.
The 3D Tissue Reforming Technology Platform is an innovative technology for producing organoid tissue modules.
By leveraging stem cell self-organization capabilities and the principles of human embryology, this platform enables the development of high-quality organoid-based regenerative therapeutics, designated as a national high-tech strategic technology.
Tissue Reforming Technology Platform (TRTP)
Organoid Tissue Module manufacturing process
Click on the photo to see a larger image.
The patient's fat is extracted to isolate and culture stem cells, which are then fabricated into micro-organoids ranging from tens to hundreds of micrometers in size. These are further developed into organoid tissue modules, with size adjustments from millimeters to centimeters, based on the Tissue Reforming Technology Platform (TRTP).
Commercially Available Organoid
CELLinCELLS addresses the critical challenges faced by existing organoid technologies (scalability, controllability, reproducibility, production time, use of artificial materials, and mass production), laying the foundation for the full commercialization of organoid-based regenerative therapeutics and enabling higher therapeutic efficacy.
Click on the photo to see a larger image.
Platform Expansion Plan
Click on the photo to see a larger image.
Organoid Advanced Regenerative Medicine
· Disc (Intervertebral Disc Disease)
· Kidney Injury Regenerative Therapeutic
· Muscle Atrophy Regenerative Therapeutic
· Charcot-Marie-Tooth Disease
· Animal Stem Cell Therapeutic
· Buerger's Disease
· Brain Injury
· Linear Scleroderma
· Burns
· Alopecia
· Pressure Ulcers (Bedsores)
· Wounds
· Atrophic Scars
· Frozen Shoulder
· Diabetic Wound (DM Wound)
· Ischemia
Tissue Reforming Technology Platform (TRTP)
Organoid Tissue Module manufacturing process
The patient's fat is extracted to isolate and culture stem cells, which are then fabricated into micro-organoids ranging from tens to hundreds of micrometers in size. These are further developed into organoid tissue modules, with size adjustments from millimeters to centimeters, based on the Tissue Reforming Technology Platform (TRTP).
Commercially Available Organoid
CELLinCELLS addresses the critical challenges faced by existing organoid technologies (scalability, controllability, reproducibility, production time, use of artificial materials, and mass production), laying the foundation for the full commercialization of organoid-based regenerative therapeutics and enabling higher therapeutic efficacy.
Platform Expansion Plan
Head Office
2nd Floor, Room 203, 240-39 Changgyeonggung-ro, Jongno-gu, Seoul, South Korea
(Gwangwon Building, Myeongnyun 4-ga)
TEL +82-2-742-0032 FAX +82-2-764-7300
Yeongeon Office
Room 501, Biomaterials Research Building, 101 Daehak-ro, Jongno-gu, Seoul, South Korea (Seoul National University School of Dentistry)
TEL +82-2-740-8641 FAX +82-2-742-8666
Munjeong Office
Room 523, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)
TEL +82-2-742-0032 FAX +82-2-764-7300
Corporate Research Institute
Rooms 513–515, Building B, 167 Songpa-daero, Songpa-gu, Seoul, South Korea (Teratower, Munjeong Station)
TECHNOLOGY
